Information Provided By: 
Fly News Breaks for June 8, 2017
RHHBY, NLNK
Jun 8, 2017 | 09:32 EDT
Stifel analyst Stephen Willey said he views Roche's (RHHBY) decision to return the rights for navoximod to NewLink Genetics (NLNK) as both "surprising" and "disappointing" and noted that the extent to which the decision was driven by asset versus mechanism of action versus competitive concerns is still unknown. However, wouldn't be selling NewLink shares into the early weakness as he still believes indoximod to be "an asset of value/interest." Willey has a Buy rating on NewLink shares.
News For NLNK;RHHBY From the Last 2 Days
There are no results for your query NLNK;RHHBY
